Amgen (NASDAQ: AMGN) recently released clinical results for its developmental weight loss drug MariTide. Shares fell by as much as 12% the next day. However, they did recover, leaving the company with only a 5% one-day loss. This decreased Amgen's value by $8 billion.
The fact that these Phase 2 Food and Drug Administration trial results had such a massive impact on Amgen’s value is telling. It shows the importance markets are placing on weight loss drugs for pharmaceutical companies competing in that arena. It highlights that this is an important topic to understand. Below, I’ll break down the MariTide results and explain their meaning within the broader weight loss drug landscape.
